US-based HyperMed Imaging has launched a new non-invasive and portable diagnostic imaging device, HyperView Imaging System, in the country.

The US Food and Drug Administration (FDA) approved, fast, handheld and battery-operated system is designed to assess tissue oxygenation and perfusion during the potential circulatory compromise.

Eliminating the need for patient contact and injectable contrast, the new device captures colour-coded images that comprise data on clinician critical information, including oxyhaemoglobin levels (Oxy), deoxyhaemoglobin levels (Deoxy) and oxygen saturation (O2Sat) in superficial tissue.

The information is intended to aid in determining the presence or absence of adequate blood perfusion required by a patient to heal a wound or maintain healthy tissue.

The imaging system is expected to allow more informed decisions on the necessary course of action by providing insights on arterial as well as venous sufficiency in the surface tissue.

“The imaging system is expected to allow more informed decisions on the necessary course of action.”

Using the HyperView system, clinicians could also obtain perfusion levels before and after vascular interventional procedures such as peripheral bypass, stent placement or balloon angioplasty.

HyperMed Imaging president and CEO Mark Darty said: “The low-cost, speed, portability, ease of use and high-quality data and imagery provide clinicians with a new class of tool to rapidly assess perfusion and locate ischemic tissue.

“This information helps caregivers better understand potential circulatory compromise and allow more informed treatment of complications of vascular disease and diabetes.”

The imaging device has applications in wound care, vascular intervention and reconstructive surgery, according to the firm’s sales vice-president Annette Plishka.